Advertisement

Topics

A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001

2014-08-27 03:42:15 | BioPortfolio

Summary

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral DR-5001 in reducing the attack rate of febrile acute respiratory disease caused by type-4 and type-7 adenovirus as well as determine its immunogenicity.

Description

The study will be conducted at two sites and will include a minimum of 4 visits. The overall study duration for participants will be approximately 8 weeks. Study participants will undergo acute respiratory disease evaluation that will include a throat swab and a blood draw. Each participant will also be contacted in six months for follow-up information.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Conditions

Respiratory Tract Diseases

Intervention

DR-5001, Placebo

Location

Duramed Investigational Site
Great Lakes
Illinois
United States
60088

Status

Completed

Source

Duramed Research

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:42:15-0400

Clinical Trials [1584 Associated Clinical Trials listed on BioPortfolio]

CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study

The purpose of this study is to assess the efficacy and safety of J022X ST for prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) compared to placebo in children of younger...

Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects

The purpose of this research study is to collect cells and liquid from the air passages of healthy adults, both smokers and non-smokers. These samples will be used for test-tube studies t...

The Effect of a Probiotic on Upper Respiratory Tract Infections

This study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group study in healthy children aged 2-6 years. The study will investigate the effect of daily intake of a...

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-...

A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections

The specific objectives of this investigation are to assess the effectiveness of daily gargling and vitamin D supplementation as preventative measures against incident upper respiratory tr...

PubMed Articles [12605 Associated PubMed Articles listed on BioPortfolio]

Reductions in otitis and other respiratory tract infections following childhood pneumococcal vaccination.

Streptococcus pneumoniae commonly causes respiratory tract infections including acute otitis media and pneumonia. In this study, we evaluated the impact of general infant pneumococcal vaccination, int...

Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by modulating macrophage phagocytic capacity.

Respiratory viruses such as respiratory syncytial virus (RSV) or rhinovirus are one of the major causes for respiratory tract infections causing common cold disease. Respiratory viral infections range...

A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.

Respiratory Syncytial Virus infection can cause lower respiratory tract infection in older adults comparable to influenza, but no vaccines are available.

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged with Respiratory Syncytial Virus: A Placebo-Controlled Study.

Respiratory syncytial virus (RSV) disease has no effective treatment. JNJ-53718678 is a fusion inhibitor with selective activity against RSV.

The Impact of Klebsiella pneumoniae in Lower Gastrointestinal Tract Diseases.

The 2016 Global Burden of Disease report by WHO revealed that diseases of the gastrointestinal tract had one of the highest incidence rates worldwide. The plethora of factors that contribute to the de...

Medical and Biotech [MESH] Definitions

Respiratory system manifestations of diseases of the respiratory tract or of other organs.

Methods and procedures for the diagnosis of diseases of the respiratory tract or its organs. It includes RESPIRATORY FUNCTION TESTS.

Diseases involving the RESPIRATORY SYSTEM.

An abnormal passage communicating between any component of the respiratory tract or between any part of the respiratory system and surrounding organs.

That part of the RESPIRATORY TRACT or the air within the respiratory tract that does not exchange OXYGEN and CARBON DIOXIDE with pulmonary capillary blood.

More From BioPortfolio on "A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...


Searches Linking to this Trial